Circular Genomics – a global leader in advancing circular RNA biomarkers for precision psychiatry and neurology – announced the closing of an $8.3 million Series A investment round. This funding round, led by Mountain Group Partners, welcomes new investor UNM Rainforest Innovations and initial investors, including Cottonwood Technology Fund, Tramway Venture Partners, and other undisclosed individuals.
The new funding round will enable Circular Genomics to build and scale commercial operations in preparation for the launch of the world’s first circular RNA-based clinical assay.
And this test is poised to improve the standard of care in depression treatment by informing clinicians of a patient’s likelihood to respond to antidepressant medications. Plus, it addresses a critical need in the healthcare system, streamlining patient care and bringing renewed hope to the millions of patients grappling with high failure rates of first-line treatments and lengthy periods of trial-and-error to find the right therapy.
Circular Genomics is at the forefront of introducing precision medicine into mental health care – promising a future where treatments are tailored for individual patients, improving outcomes, and providing deeper understanding of these complex conditions.
KEY QUOTES:
“Precision psychiatry, driven by circular RNA biomarkers, equips physicians with a biomarker-based approach towards personalized care for patients fighting major depression. We plan to launch our first test in 2024, which will predict response to SSRI antidepressants, addressing the issue of high therapy failure rates, and low clinical outcomes. Furthermore, the launch of this first assay paves the way for a set of tests covering the complete patient care continuum in major depression, and using the same circular RNA platform, in other neurological diseases too.”
— Dr. Paul Sargeant, CEO, Circular Genomics
“We are excited to support Circular Genomics in advancing the development of the circular RNA biomarker platform. The expansion of this platform holds the potential to dramatically improve patient outcomes and broaden our understanding of psychiatric and neurological conditions.”
— Joe Cook, III, Managing Partner of Mountain Group Partners
